2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 125

Increased Hypertension and Renal Disease in African Americans Compared to Caucasians with Systemic Lupus Erythematosus

Healthcare Disparities in Rheumatology - Poster I

9:00AM-11:00AM: Abstract Number: 358

Increased Infection Risk with Concomitant Use of RANK Ligand-Inhibitor, Denosumab and TNF-Inhibitors or Other Biologics: Reality or Illusion? Long Term Experience at the University of Southern California

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 104

Incremental Direct Expenditures Due to Osteoarthritis: A Nationally Representative Study Using Medical Expenditure Panel Survey Data

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 868

Infections and the Risk of Incident Giant Cell Arteritis: A Population-Based, Case-Control Study

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 111

Influences of Osteoarthritis Pain, Comorbid Insomnia, and Depression on Health Care Use in Older Adults with Osteoarthritis

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 608

Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 376

Initial Validation of the Patient Reported Outcomes Measurement Information System Pediatric Pain Intensity Scale in Juvenile Idiopathic Arthritis, Juvenile Fibromyalgia and Sickle Cell Disease

Pain – Basic and Clinical Aspects - Poster

9:00AM-11:00AM: Abstract Number: 77

Integrated Analysis of Microrna and mRNA Expression Profiles Related to Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome Patients

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 207

Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout

Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

9:00AM-11:00AM: Abstract Number: 109

Inter-Professional Satisfaction and Perceptions of Collaborative Practice of an Innovative Model of Care for the Early Detection of Axial Spondyloarthritis

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 346

Interest of Bone Texture Assessment By Trabecular Bone Score (TBS) in Kidney Transplants Recipients

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 272

Interferon Chemokine Score and Other Cytokine Measures Predict Changes in Disease Activity in Patients with Juvenile and Adult Dermatomyositis

Muscle Biology, Myositis and Myopathies - Poster I: Basic/Translational

9:00AM-11:00AM: Abstract Number: 871

Interleukin 33 Critically Regulates Angiogenesis and Inflammation in Large Vessels Vasculitis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 467

Interleukin-21-Signaling in B Cells, but Not in T Cells, Is Indispensable for Development of Collagen-Induced Arthritis in Mice

Rheumatoid Arthritis – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 873

Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].